1. Home
  2. LGO vs LCTX Comparison

LGO vs LCTX Comparison

Compare LGO & LCTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • LGO
  • LCTX
  • Stock Information
  • Founded
  • LGO 1988
  • LCTX 1990
  • Country
  • LGO Canada
  • LCTX United States
  • Employees
  • LGO N/A
  • LCTX N/A
  • Industry
  • LGO
  • LCTX Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • LGO
  • LCTX Health Care
  • Exchange
  • LGO Nasdaq
  • LCTX Nasdaq
  • Market Cap
  • LGO 91.0M
  • LCTX 107.3M
  • IPO Year
  • LGO 2007
  • LCTX N/A
  • Fundamental
  • Price
  • LGO $1.59
  • LCTX $1.13
  • Analyst Decision
  • LGO Strong Buy
  • LCTX Strong Buy
  • Analyst Count
  • LGO 1
  • LCTX 5
  • Target Price
  • LGO $3.70
  • LCTX $4.20
  • AVG Volume (30 Days)
  • LGO 183.8K
  • LCTX 3.1M
  • Earning Date
  • LGO 08-07-2025
  • LCTX 08-07-2025
  • Dividend Yield
  • LGO N/A
  • LCTX N/A
  • EPS Growth
  • LGO N/A
  • LCTX N/A
  • EPS
  • LGO N/A
  • LCTX N/A
  • Revenue
  • LGO $110,968,000.00
  • LCTX $9,557,000.00
  • Revenue This Year
  • LGO $23.62
  • LCTX N/A
  • Revenue Next Year
  • LGO $41.27
  • LCTX $232.66
  • P/E Ratio
  • LGO N/A
  • LCTX N/A
  • Revenue Growth
  • LGO N/A
  • LCTX 19.42
  • 52 Week Low
  • LGO $1.12
  • LCTX $0.37
  • 52 Week High
  • LGO $2.84
  • LCTX $1.21
  • Technical
  • Relative Strength Index (RSI)
  • LGO 59.69
  • LCTX 64.55
  • Support Level
  • LGO $1.54
  • LCTX $0.93
  • Resistance Level
  • LGO $1.68
  • LCTX $1.02
  • Average True Range (ATR)
  • LGO 0.11
  • LCTX 0.09
  • MACD
  • LGO 0.02
  • LCTX 0.00
  • Stochastic Oscillator
  • LGO 55.00
  • LCTX 71.43

About LGO Largo Inc.

Largo Inc is committed to the production and supply of high-quality vanadium products. The company is also focused on the advancement of renewable energy storage solutions through Largo Clean Energy and its vanadium redox flow battery technology. The Company is engaged in the mining, exploration, and development of mineral properties, predominantly in Brazil, through which it produces and supplies vanadium products VPURE Flake, VPURE+ Flake, and VPURE+ Powder. The company has operating segments: sales & trading, mine properties, which generates key revenue, corporate, exploration and evaluation properties, Clean Energy, and Largo Physical Vanadium.

About LCTX Lineage Cell Therapeutics Inc.

Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline is based on two platform technologies including cell replacement and cell/drug delivery. Lineage Cell's product candidate is OpRegen, a retinal pigment epithelium transplant therapy for the treatment of dry age-related macular degeneration, OPC1, an oligodendrocyte progenitor cell therapy for acute spinal cord injuries, and VAC2, allogeneic cancer immunotherapy of antigen-presenting dendritic cells for non-small cell lung cancer, ANP1, an allogeneic auditory neuron progenitor cells transplant for hearing loss, and PNC1, an allogeneic photoreceptor cell transplant for vision loss.

Share on Social Networks: